• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by VALNEVA

< Previous 1 2 3 4 Next >
News headline image
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom
February 13, 2026
From VALNEVA
Via GlobeNewswire
News headline image
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
February 03, 2026
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
January 19, 2026
From VALNEVA
Via GlobeNewswire
News headline image
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
January 09, 2026
From VALNEVA
Via GlobeNewswire
News headline image
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
December 31, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
December 10, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva to Further Consolidate its Operations in France
November 26, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
November 26, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
November 20, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
November 04, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
October 27, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
October 06, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
September 30, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
September 03, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
August 25, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
August 18, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
August 12, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
August 07, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
July 11, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
June 26, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
June 25, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
June 05, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
June 04, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva to Participate at U.S. and European Investor Conferences in June
May 26, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
May 12, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
May 07, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 07, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
April 26, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
April 18, 2025
From VALNEVA
Via GlobeNewswire
News headline image
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
April 16, 2025
From VALNEVA
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap